Introduction: The objective of this study was to
INTRODUCTION
Diabetes affects more than 8.3% of the total population and is the seventh leading cause of death in the United States (US) [1] . The total estimated direct and indirect costs of treating diabetes in the US were $176 billion and $69 billion, respectively, in 2012 [2] . Type 2 diabetes mellitus (T2DM) accounts for 90-95% of all diagnosed cases of diabetes [1] .
The key to managing diabetes is optimal glycemic control, while minimizing the risk of experiencing hypoglycemia, which is associated with significant reduction in the development of microvascular and macrovascular complications [3] [4] [5] .
While lifestyle modifications such as healthy eating and exercise can help control glycemia, pharmacological agents remain the mainstream treatment to maintain target glucose levels, especially due to the progressive nature of diabetes. Incretin-based therapies for the management of T2DM are effective in lowering glycated hemoglobin A1c (A1C) with a low risk of hypoglycemia [6] [7] [8] . These Head-to-head trials of liraglutide versus sitagliptin have shown that liraglutide is superior to sitagliptin for glycemic control and weight loss [10] [11] [12] . Patients on liraglutide also reported greater treatment satisfaction than those using sitagliptin [13] . However, there are few studies assessing the real-world comparative effectiveness of these drugs. The economic implication of the clinical effectiveness of liraglutide versus sitagliptin is unknown in the US. This study aims to address this knowledge gap by comparing the real-world clinical and economic outcomes among persistent liraglutide and sitagliptin patients for the treatment of T2DM.
METHODS

Data Source
This retrospective observational study utilized data from the Truven Health MarketScan [18] .
Clinical and Economic Outcomes
Glycemic outcomes at 6 months of follow-up were measured by the following clinical endpoints: absolute change in A1C from baseline and A1C goal attainment of B6.5%
and \7% as recommended by the American Association of Clinical Endocrinologists [19] and American Diabetes Association [20] , respectively. The follow-up A1C measure was defined as the value closest to day 180 postindex within a ±45-day window, while baseline A1C was defined as the value closest to the index date within a window of 45 days prior to 7 days after the index date. Economic outcomes assessed were total healthcare costs related to T2DM over the 6 months of follow-up, stratified by diabetesrelated medical costs and pharmacy costs for anti-diabetic medications. These costs were identified from medical claims with a primary or secondary diagnosis code for diabetes (ICD-9-CM 250.xx), and pharmacy claims for oral antidiabetic medication, non-insulin injectables (exenatide or liraglutide), and insulin. All costs were adjusted to 2013 values based on
Consumer Price Index Medical Component [21] .
Statistical Analysis
The study measures between treatment groups were compared using Student's t test, Chisquare test, and Wilcoxon rank-sum test for continuous, categorical, and cost variables, respectively. Multivariable regression models were used to assess the association between the index therapy (liraglutide or sitagliptin) and the outcomes. The model specifications were based on the distribution of the outcomes.
Absolute changes in A1C were assessed using ordinary least square regression, A1C goal attainment was assessed using logistic regression, and economic outcomes (total, medical, and pharmacy costs related to T2DM)
were assessed using generalized linear models with a log link and gamma distribution. All regression models adjusted for baseline patient characteristics, including demographics and clinical characteristics, baseline A1C, and total healthcare costs related to T2DM during the 6-month washout period. Adjusted ratios of the outcomes associated with liraglutide and with sitagliptin were reported, including the odds ratio (OR) for the A1C goal attainment and the cost ratio (CR) for the economic outcomes.
Adjusted values of the outcomes were calculated from the regression results using the method of recycled predictions, in which the adjusted outcomes were predicted twice for each patient in the sample, once assuming liraglutide and the other time assuming sitagliptin as the index therapy, respectively [22] . Data were compiled and analyzed using SAS (version 9.4, SAS Institute Inc., Cary, NC).
RESULTS
A Multivariable regression models were used to adjust for differences in baseline patient characteristics, including demographic and clinical characteristics, baseline A1C, and total healthcare costs related to T2DM during the 6-month washout period. These regression results were then used to predict the adjusted outcomes. The adjusted reduction of A1C at 6-month follow-up from baseline was predicted to be on average 0.31% points higher for liraglutide patients than sitagliptin patients (0.95% points vs. 0.63% points; P\0.01; Table 4 ). Correspondingly, a higher proportion 
DISCUSSION
This is the first study to provide integrated evidence on the clinical effectiveness and the associated economic impact of treatment with liraglutide versus sitagliptin in real-world clinical practice in the US. In this intent-totreat study, multivariable regressions were used to adjust for the differences in baseline patient demographics (such as age and gender) and clinical characteristics (such as baseline A1C level and diabetes-related costs) between patients initiating liraglutide and sitagliptin. Liraglutide patients showed significantly greater reduction in A1C and were more likely to achieve A1C targets than sitagliptin patients at 6 months of follow-up. The improved glycemic control associated with liraglutide compared with sitagliptin had economic implications.
Despite higher pharmacy costs, liraglutide patients had significantly lower medical costs related to the management of T2DM over the 6 months follow-up compared with sitagliptin The clinical results of this study are consistent with the previously published findings from real-world practice. The study by Lee et al. [23] compared glycemic outcomes at 6 months of follow-up among adult patients with T2DM who initiated liraglutide, exenatide, or sitagliptin. Their study demonstrated that liraglutide patients had 0.40% points greater reduction in mean A1C (1.08% points vs. 0.68% points; P\0.01) and a higher proportion attaining A1C target of \7% (64.4% vs. 49.4%; P\0.01) at 6 months of follow-up than sitagliptin patients [23] . Another study, based on T2DM patients who were treated with at least 3 months of incretin-based therapies in mean baseline A1C: 8.5%) [11] . In this trial, mean A1C reductions for liraglutide 1.2 mg (1.24% points) and 1.8 mg (1.50% points) were superior to those of sitagliptin (0.90% points) (both P\0.01 compared with sitagliptin). A 26-week extension yielded similar results, with mean A1C reductions of 1.29% points, 1.51% points, and 0.88% points, respectively (both P\0.01 compared with sitagliptin) [10] . The efficacy of liraglutide in this clinical trial, in terms of absolute mean reduction in A1C, is slightly higher than the clinical effectiveness found in our study (0.95% points adjusted mean reduction in A1C at 6-month follow-up) but the relative treatment effects of liraglutide versus sitagliptin are comparable. The higher absolute reduction in A1C associated with A1C Glycated hemoglobin A1c, SD standard deviation * P values were determined using t tests for continuous variables, the Chi-square test for categorical variables, and Wilcoxon rank-sum test for cost variables, to assess statistical significance 
CONCLUSION
In real-world clinical practice in the US, liraglutide provides significantly greater improvements in clinical outcomes as compared with sitagliptin, without any increase in total diabetes-related costs over 6 months of follow-up. This information could be used to guide therapeutic decision makers to make cost-effective decisions for treatment of patients with T2DM.
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